Review of TA52; Drugs for early thrombolysis in the treatment of acute myocardial infarction, and TA230; Bivalirudin for the treatment of ST-segment elevation myocardial infarction (STEMI)

The Institute was proposing that TA52 and TA230 should be incorporated verbatim into the ongoing clinical guideline on the ‘management of acute coronary syndromes including myocardial infarction’. 

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Therefore, both TA52 and TA230 will be incorporated into the ongoing clinical guideline, and guideline developers will be able to supplement the recommendations by placing them in the context of current clinical practice.  As a result, TA230 will be moved to the static list of technology appraisals and TA52 will remain on the static list until such a time as the guideline is updated.  This will preserve the funding direction for TA52 and TA230.